94 results on '"Dezzutti, Charlene S."'
Search Results
2. Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring
3. Vaginal Product Formulation Alters the Innate Antiviral Activity and Glycome of Cervicovaginal Fluids with Implications for Viral Susceptibility
4. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir
5. Cryopreservation of human mucosal tissues
6. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women
7. Cryopreservation of human mucosal tissues
8. Heterogeneity of HIV-1 Replication in Ectocervical and Vaginal Tissue Ex Vivo
9. Analytical Advances in the Ex Vivo Challenge Efficacy Assay
10. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
11. The Effect of Commonly Used Excipients on the Epithelial Integrity of Human Cervicovaginal Tissue
12. Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir
13. Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial
14. Cryopreservation of Human Mucosal Leukocytes
15. Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue
16. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film
17. Impact of Microbicide Formulation on Glycosylation and Innate Immunity in Cervicovaginal Fluid
18. testCryopreservation of human mucosal leukocytes
19. Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo
20. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings
21. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel
22. Assessing the potential of the Woman’s Condom for vaginal drug delivery
23. The effect of menopause on the innate antiviral activity of cervicovaginal lavage
24. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention
25. Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women
26. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention
27. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)
28. Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission
29. Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?
30. Y Chromosome and HIV DNA Detection in Vaginal Swabs as Biomarkers of Semen and HIV Exposure in Women
31. Expression, Activity, and Regulation of Phosphorylating Enzymes in Genital and Colorectal Tissues and Immune Cells
32. Topical Application of Broadly Neutralizing Monoclonal Antibodies Reduces HIV Infection of Mucosal Tissue
33. Defining Pharmacokinetic and Pharmacodynamic linkages between Genital Tissue and Lumen Compartments
34. Development of a DuoGel for Vaginal and Rectal Delivery of Microbicide Products
35. DuoGel™: The Development of A Multi-drug Dual Chamber Vaginal/Rectal Anti-HIV Microbicide Gel
36. Design of Biodegradable Nanoparticles for Vaginal Delivery of the anti-HIV Protein Griffithsin
37. Use of the ICCA to Predict Dosing of HIV Microbicide Products to Achieve Virus Sterilization in Target Tissue
38. Formulation and Characterization of Polymeric Films Containing Combinations of Antiretrovirals (ARVs) for HIV Prevention
39. HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities
40. Development of HIV-1 Rectal-Specific Microbicides and Colonic Tissue Evaluation
41. Antiviral Activity of Genital Tract Secretions After Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1
42. Toward Early Safety Alert Endpoints: Exploring Biomarkers Suggestive of Microbicide Failure
43. HIV-1 Infection of Female Genital Tract Tissue for Use in Prevention Studies
44. Use of Human Mucosal Tissue to Study HIV-1 Pathogenesis and Evaluate HIV-1 Prevention Modalities
45. Erratum to: Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices
46. Is Wetter Better? An Evaluation of Over-the-Counter Personal Lubricants for Safety and Anti-HIV-1 Activity
47. Safety and efficacy of tenofovir/IQP-0528 combination gels – A dual compartment microbicide for HIV-1 prevention
48. Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices
49. Sublimable C5A Delivery Provides Sustained and Prolonged Anti-HIV Microbicidal Activities
50. Characterization of UC781-Tenofovir Combination Gel Products for HIV-1 Infection Prevention in an Ex Vivo Ectocervical Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.